Related Experiment Video
Updated: May 20, 2026

Multi-photon Intracellular Sodium Imaging Combined with UV-mediated Focal Uncaging of Glutamate in CA1 Pyramidal Neurons
Published on: October 8, 2014
ACS chemical neuroscience molecule spotlight on semagacestat (LY450139)
1Department of Pharmacology and Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, USA.
Abstract:
Semagacestat (LY450139) is a novel γ-secretase inhibitor currently in late-stage development by Eli Lilly and Company as a potential treatment for Alzheimer's disease (AD). Semagacestat is currently being studied in two phase III clinical trials.
More Related Videos
08:23Real-Time Impedance-based Cell Analyzer as a Tool to Delineate Molecular Pathways Involved in Neurotoxicity and Neuroprotection in a Neuronal Cell Line
Published on: August 9, 2014
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019